Literature DB >> 1684096

Biological correlation between HER-2/neu and proliferative activity in human breast cancer.

S Tommasi1, A Paradiso, A Mangia, A Barletta, G Simone, D J Slamon, M De Lena.   

Abstract

HER-2neu alterations (amplification and overexpression), proliferative activity (3H-Thymidine-Labeling Index, 3H-Tdr-LI) and tumor ploidy (flow-cytometry) were analyzed in a human breast cancer series. Overexpressed tumors showed a significantly higher median 3H-Tdr-LI than normally expressed (p = 0.04), as also did amplified/overexpressed with respect to non-amplified/normally expressed (p less than 0.04). These differences were confirmed only in N-primary tumors. In fact, high expressed cases demonstrated a median 3H-Tdr-LI of 5.5% with respect to 1.9% for low expressed cases (p = 0.04) and amplified/overexpressed had a 3H-Tdr-LI of 9% with respect to 2% for non amplified/low expressed (p = 0.009). HER-2/neu alterations were not correlated with tumor DNA content.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1684096

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.

Authors:  A A Keshgegian
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

2.  A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.

Authors:  Derrick S Haslem; S Burke Van Norman; Gail Fulde; Andrew J Knighton; Tom Belnap; Allison M Butler; Sharanya Rhagunath; David Newman; Heather Gilbert; Brian P Tudor; Karen Lin; Gary R Stone; David L Loughmiller; Pravin J Mishra; Rajendu Srivastava; James M Ford; Lincoln D Nadauld
Journal:  J Oncol Pract       Date:  2016-10-31       Impact factor: 3.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.